Yeast Chassis Genome Integration Patents: Top Filers & Trends 2026
- 31.5% concentration at the top. The five leading assignees together hold 1,939 of 6,161 records in scope — filing here is not evenly spread.
- Filing has cooled from its 2018 peak. Records ran from 135 in 2017 to a peak of 261 in 2018, then fell 43% from 2021 (137) to 2024 (78), the most recent complete year.
- Measurement claims sit next to engineering claims. C12Q (measuring/testing) reaches 51.0% of records alongside C12N (91.7%), showing assay and detection work filed tightly around the host-cell engineering itself.
Filing growth compares 2021 (137 records) with 2024 (78) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 6,161 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent records at the intersection of engineered yeast host cells and the mechanics of getting DNA to sit stably in the genome: integration sites, homology arms, copy number control, marker excision and recombination efficiency. The search spans C12N15/81 (yeast genetic engineering), C12N1/16 (yeast micro-organisms) and C12Q1/68 (nucleic acid measuring), which is why the technology composition below shows heavy overlap between engineering classes and measurement/testing classes.
Coverage runs from 2015-01-01 to the 2026-07-31 cut-off, giving 6,161 published records. Because publication trails filing by roughly 18 months, the 2025 and 2026 counts in the trend chart are still filling in and should not be read as a genuine drop-off.
Filing trend and technology composition
Two views of the same 6,161-record dataset: how filing volume has moved year over year, and which IPC subclasses the records sit in.
Filing trend, 2017–2026
Records rose from 135 in 2017 to a peak of 261 in 2018, then eased through the following years; the 2021-to-2024 span shows a 43% decline (137 to 78), the most recent window unaffected by publication lag. 2025 and 2026 figures are partial and will revise upward as filings publish.
Technology composition by IPC subclass
C12N covers 91.7% of the 6,161 records, confirming this is fundamentally a genetic-engineering corpus. C07K (57.3%) and C12P (51.4%) point to heavy overlap with protein/peptide expression and fermentation output, while C12Q (51.0%) and G01N (28.4%) show a large share of records also claim the assay or measurement side of confirming integration and stability, not just the construct itself.
Shares are the percentage of the 6,161 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Yeast Chassis Genome Integration with Eureka
This page is one run against one query. Ask Eureka your own question about yeast chassis genome integration and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited records
Modulation of formate oxidation by recombinant yeast host cell during fermentation (US20220002661A1)
Filed by Danstar Ferment AG, this record concerns recombinant yeast host cells carrying a first genetic modification that increases formate production relative to a native yeast host cell, paired with a source of formate dehydrogenase activity. That source can be internal to the engineered strain or supplied externally during fermentation.Published 2022-01-06 — illustrates how fermentation-performance claims are now being layered onto host-cell engineering claims rather than filed separately.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO1995022625A1 | DNA mutagenesis by random fragmentation and reassembly | 4,100 |
| 2 | US5811238A | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination | 3,258 |
| 3 | US5830721A | DNA mutagenesis by random fragmentation and reassembly | 2,982 |
| 4 | WO2000024883A1 | Constructing and screening a DNA library of interest in filamentous fungal cells | 1,794 |
| 5 | US4965199A | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection | 1,553 |
| 6 | US6204023B1 | Modular assembly of antibody genes, antibodies prepared thereby and use | 1,334 |
| 7 | WO1998027230A1 | Methods and compositions for polypeptide engineering | 1,315 |
| 8 | US5965408A | Method of DNA reassembly by interrupting synthesis | 1,284 |
| 9 | WO1995019431A1 | Zinc finger protein derivatives and methods therefor | 1,119 |
| 10 | WO1997020078A1 | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination | 1,098 |
Citation counts favour older records simply because they have had longer to accumulate citations inside this corpus; treat them as a signal of foundational influence, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say
Reading the concentration, trend and citation data together points to a field with an entrenched early core and a large, active periphery.
Filing is concentrated but not closed
The five leading assignees hold 1,939 of 6,161 records (31.5%), and the ranked ten hold 2,522 (40.9%). That still leaves the majority of records spread across a long tail of single- and few-filing entrants, so an entrenched core coexists with real room to file distinct claims.
Volume has come off its 2018 peak
Filing peaked at 261 records in 2018 and has since declined, with the 2021-to-2024 window down 43% (137 to 78). None of the historically leading assignees show filings in the latest year, consistent with a first wave of core IP already staked out.
Engineering claims travel with assay claims
Just over half of records sit in C12Q alongside the 91.7% in C12N, meaning integration and stability work is routinely claimed together with the methods used to confirm it — copy number assays, recombination-efficiency measurement, genomic stability testing.
Filing is US- and Europe-weighted, with PCT close behind
The United States leads with 1,982 records, ahead of the EPO at 1,126 and WIPO/PCT at 1,009. Australia, Canada and Israel each carry meaningfully smaller but non-trivial counts, indicating deliberate multi-jurisdiction strategies rather than single-market filing.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to yeast chassis genome integration, with the prior art for and against each one.
Who is filing, and what is still open
The assignee ranking covers 100 companies returned by the dataset — not a curated top-50 or top-100 list, but the full ranking the data endpoint returns. A small core of early filers, several tied to human genome and biologics work, sits alongside industrial biotech and fermentation specialists.
One assignee holds a disproportionate share
The leading assignee alone accounts for 1,010 records, dwarfing the fifth-place total of 155 and tenth-place total of 91. Much of this concentration traces back to a cluster of co-filed records among a small group of named inventors and their affiliated corporate entity, visible in the strongest co-assignee pairings in this dataset.
Fermentation specialists file alongside genome-engineering firms
Enzyme and fermentation specialists appear throughout the ranking, reflecting the corpus's dual identity: genome integration mechanics filed by biotech firms sit next to fermentation and enzyme-production claims from industrial biotech companies.
No leading assignee shows fresh filings
Every one of the historically dominant assignees, including the top-ranked entity and its named co-filers, shows zero records in the latest year, with at least one showing a -100% year-over-year change. That is consistent with core claims being staked early and the current wave of activity coming from newer or smaller filers not yet visible at the top of the ranking.
| Assignee | Recent year | YoY |
|---|---|---|
| Human Genome Sciences, Inc. | 0 | — |
| ROSEN CRAIG A | 0 | — |
| RUBEN STEVEN M | 0 | — |
| Novozymes A/S | 0 | -100% |
| BARASH STEVEN C | 0 | — |
| Lonza AG | 0 | — |
| Diversa Corporation | 0 | — |
| Bristol-Myers Squibb Company | 0 | — |
Where to take this
The landscape data points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or identifying open filing space.
Check claim scope on the concentrated core
With 31.5% of records held by five assignees, any new filing on integration-site selection or copy-number control should be checked against that core before drafting.
Explore claims in EurekaMap the measurement-side overlap
The 51.0% overlap with C12Q suggests assay and detection claims are being filed alongside host-cell engineering; treat them as one search, not two.
Run a combined search in EurekaTrack the newer, smaller filers
Zero latest-year activity from the historic leaders means current momentum sits with assignees outside the top of the ranking; a fresh assignee pull is worth running periodically.
Set up monitoring in EurekaCommon questions on this landscape
One assignee leads clearly with 1,010 of the 6,161 records in scope, well ahead of the fifth-place assignee at 155 and tenth place at 91. Much of that leader's volume traces to a small cluster of co-filed records with named individual inventors, visible in the strongest co-assignee pairings in the dataset. Together the top five assignees hold 31.5% of all records, so while there is a clear leader, the majority of filings still come from a long tail of smaller players.
Filing peaked in 2018 at 261 records and has declined since, with a 43% drop from 137 records in 2021 to 78 in 2024 — the most recent year that can be treated as complete. Figures for 2025 and 2026 look lower still, but that reflects publication lag of roughly 18 months rather than an actual collapse in filing activity. Read the 2021-to-2024 window as the reliable signal, not the raw tail end of the chart.
US20220002661A1, assigned to Danstar Ferment AG and published 2022-01-06, covers recombinant yeast host cells engineered to increase formate production relative to a native strain, combined with a source of formate dehydrogenase activity that can be internal or externally supplied during fermentation. It is a fermentation-performance patent layered on top of host-cell engineering rather than a claim over integration mechanics themselves. Anyone modifying yeast formate metabolism for fermentation should review its specific claim language before designing a similar pathway.
The composition data shows dense overlap between core engineering claims (C12N, 91.7% of records) and downstream assay claims (C12Q, 51.0%), but thinner activity in specific mechanical variants such as marker-free excision recombinase systems, non-homologous end-joining-based site selection, and copy-number-tunable promoter cassettes. These sit adjacent to the crowded core without being as heavily claimed themselves. That makes them worth a freedom-to-operate check before assuming the space is closed, since low density does not guarantee an easy path but does suggest less prior art congestion.
The United States receives the most filings at 1,982 records, followed by the European Patent Office at 1,126 and the WIPO/PCT route at 1,009. Australia (648), Canada (427) and Israel (158) round out meaningful but smaller filing volumes. The spread across these offices indicates that serious filers in this space pursue multi-jurisdiction protection rather than relying on a single market filing.
Research Yeast Chassis Genome Integration in depth with Eureka
Go past this page: query the whole yeast chassis genome integration corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.